News
7/9/2011
Boehringer Ingelheim wins Frost & Sullivan Award 2011 for outstanding service in the Biopharmaceutical Contract Manufacturing
Bracknell, England, September 7, 2011 – Boehringer Ingelheim has received the '2011 European Bio Pharmaceutical Contract Manufacturing Competitive Strategy Leadership Award' from Frost & Sullivan.
The analysts of Frost & Sullivan recognized Boehringer Ingelheim Biopharmaceuticals as a global contract manufacturer who delivers excellence and best practices to its customers and collaboration partners. The Boehringer Ingelheim performance was measured against key competitors in the same market focusing on the criteria: leverage of competitive intelligence, execution of competitive strategy, impact on market share, competitive brand positioning and impact on customer satisfaction and value.
"This award is an important recognition for our contract manufacturing organization and a great confirmation for continued drive to put our customers first”, stated Simon Sturge, Corporate Senior Vice President Biopharmaceuticals at Boehringer Ingelheim. “We will not rest on our laurels and will continue to further improve our customer services to also deliver reliable and best quality in the future. With our newly acquired biopharma development- and manufacturing facility in Fremont, California, Boehringer Ingelheim has already taken the next important step to further strengthen our global customer orientation and flexibility”.
Contact:
Duncan Cantor
Director of Communications44 (0)1344 74 1155
Duncan.Cantor@boehringer-ingeheim.com
Twitter: @BoehringerUK
More information:
www.biopharma-cmo.com
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
A central element of Boehringer Ingelheim’s culture is to be socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.
In 2010, Boehringer Ingelheim posted net sales of about 12.6 billion euro while spending almost 24% of net sales in its largest business segment Prescription Medicines on research and development.
For more information please visit www.boehringer-ingelheim.co.uk
This news story was brought to you by Boehringer Ingelheim - the largest family-owned pharmaceutical company in the world.
What do you want to do now?
|
|
||
